Gene & Cell Therapy FAQs | ASGCT – American Society of …
By Dr. Matthew Watson
The challenges of gene and cell therapists can be divided into three broad categories based on disease, development of therapy, and funding.
Challenges based on the disease characteristics: Disease symptoms of most genetic diseases, such as Fabrys, hemophilia, cystic fibrosis, muscular dystrophy, Huntingtons, and lysosomal storage diseases are caused by distinct mutations in single genes. Other diseases with a hereditary predisposition, such as Parkinsons disease, Alzheimers disease, cancer, and dystonia may be caused by variations/mutations in several different genes combined with environmental causes. Note that there are many susceptible genes and additional mutations yet to be discovered. Gene replacement therapy for single gene defects is the most conceptually straightforward. However, even then the gene therapy agent may not equally reduce symptoms in patients with the same disease caused by different mutations, and even the samemutationcan be associated with different degrees of disease severity. Gene therapists often screen their patients to determine the type of mutation causing the disease before enrollment into a clinical trial.
The mutated gene may cause symptoms in more than one cell type. Cystic fibrosis, for example, affects lung cells and the digestive tract, so the gene therapy agent may need to replace the defective gene or compensate for its consequences in more than one tissue for maximum benefit. Alternatively, cell therapy can utilizestem cellswith the potential to mature into the multiple cell types to replace defective cells in different tissues.
In diseases like muscular dystrophy, for example, the high number of cells in muscles throughout the body that need to be corrected in order to substantially improve the symptoms makes delivery of genes and cells a challenging problem.
Some diseases, like cancer, are caused by mutations in multiple genes. Although different types of cancers have some common mutations, every tumor from a single type of cancer does not contain the same mutations. This phenomenon complicates the choice of a single gene therapy tactic and has led to the use of combination therapies and cell elimination strategies. For more information on gene and cell therapy strategies to treat cancer, please refer to the Cancer and Immunotherapy summary in the Disease Treatment section.
Disease models in animals do not completely mimic the human diseases and viralvectorsmay infect various species differently. The testing of vectors in animal models often resemble the responses obtained in humans, but the larger size of humans in comparison to rodents presents additional challenges in the efficiency of delivery and penetration of tissue.Gene therapy, cell therapy, and oligonucleotide-based therapy agents are often tested in larger animal models, including rabbit, dog, pig and nonhuman primate models. Testing human cell therapy in animal models is complicated by immune rejections. Furthermore, humans are a very heterogeneous population. Their immune responses to the vectors, altered cells, or cell therapy products may differ or be similar to results obtained in animal models.
Challenges in the development of gene and cell therapy agents: Scientific challenges include the development of gene therapy agents that express the gene in the relevant tissue at the appropriate level for the desired duration of time. There are a lot of issues in that once sentence, and while these issues are easy to state, each one requires extensive research to identify the best means of delivery, how to control sufficient levels or numbers of cells, and factors that influence duration of gene expression or cell survival. After the delivery modalities are determined, identification and engineering of a promoter and control elements (on/off switch and dimmer switch) that will produce the appropriate amount of protein in the target cell can be combined with the relevant gene. This gene cassette is engineered into a vector or introduced into thegenomeof a cell and the properties of the delivery vehicle are tested in different types of cells in tissue culture. Sometimes things go as planned and then studies can be moved onto examination in animal models. In most cases, the gene/cell therapy agent may need to be improved further by adding new control elements to obtain the desired responses in cells and animal models.
Furthermore, the response of the immune system needs to be considered based on the type of gene or cell therapy being undertaken. For example, in gene or cell therapy for cancer, one aim is to selectively boost the existing immune response to cancer cells. In contrast, to treat genetic diseases like hemophilia and cystic fibrosis the goal is for the therapeutic protein to be accepted as an addition to the patients immune system.
If the new gene is inserted into the patients cellularDNA, the intrinsic sequences surrounding the new gene can affect its expression and vice versa. Scientists are now examining short DNA segments that may insulate the new gene from surrounding control elements. Theoretically, these insulator sequences would also reduce the effect of vector control signals in the gene cassette on adjacent cellular genes. Studies are also focusing on means to target insertion of the new gene into safe areas of the genome, to avoid influence on surrounding genes and to reduce the risk of insertional mutagenesis.
Challenges of cell therapy include the harvesting of the appropriate cell populations and expansion or isolation of sufficient cells for one or multiple patients. Cell harvesting may require specific media to maintain the stem cells ability toself-renew and mature into the appropriate cells. Ideally extra cells are taken from the individual receiving therapy. Those additional cells can expand in culture and can be induced to becomepluripotent stem cells(iPS), thus allowing them to assume a wide variety of cell types and avoiding immune rejection by the patient. The long term benefit of stem cell administration requires that the cells be introduced into the correct target tissue and become established functioning cells within the tissue. Several approaches are being investigated to increase the number of stem cells that become established in the relevant tissue.
Another challenge is developing methods that allow manipulation of the stem cells outside the body while maintaining the ability of those cells to produce more cells that mature into the desired specialized cell type. They need to provide the correct number of specialized cells and maintain their normal control of growth and cell division, otherwise there is the risk that these new cells may grow into tumors.
Challenges in funding: In most fields, funding for basic or applied research for gene and cell therapy is available through the National Institutes of Health (NIH) and private foundations. These are usually sufficient to cover the preclinical studies that suggest a potential benefit from a particular gene and cell therapy. Moving into clinical trials remains a huge challenge as it requires additional funding for manufacturing of clinical grade reagents, formal toxicology studies in animals, preparation of extensive regulatory documents, and costs of clinical trials.Biotechnology companies and the NIH are trying to meet the demand for this large expenditure, but many promising therapies are slowed down by lack of funding for this critical next phase.
See original here:
Gene & Cell Therapy FAQs | ASGCT - American Society of ...
- Induction of muscle-regenerative multipotent stem cells from human adipocytes by PDGF-AB and 5-azacytidine - Science Advances - January 14th, 2021
- A Potential Therapy for One of the Leading Causes of Heart Disease - PRNewswire - December 10th, 2020
- Evotec and Sartorius Partner with Start-Up Curexsys on IPSC-Based Therapeutic Exosome Approach - BioSpace - December 9th, 2020
- Induced Pluripotent Stem Cell (iPS Cell) Applications in 2020 - November 28th, 2020
- Induced Pluripotent Stem Cell - an overview ... - November 28th, 2020
- The Stem Cell-Derived Cells market to Scale new heights in the next decade - Khabar South Asia - November 28th, 2020
- Stem Cells Market 2020: Rising with Immense Development Trends across the Globe by 2027 - The Market Feed - November 25th, 2020
- The Stem Cell-Derived Cells Market to witness explicit growth from 2019 and 2029 - The Haitian-Caribbean News Network - November 23rd, 2020
- Stem Cells Market Research Provides an In-Depth Analysis on the Future Growth Prospects and Industry Trends Adopted by the Competitors | (2020-2027),... - November 23rd, 2020
- The Stem Cell-Derived Cells market to go the astute way from 2019 to 2029 - TechnoWeekly - November 3rd, 2020
- Global Stem Cells Market 2020 Industry Demand, Share, Global Trend, Top Key Players Update, Business Statistics And Research Methodology By Forecast... - November 3rd, 2020
- Regenerative Medicine in Cosmetic Dermatology | MDedge ... - October 30th, 2020
- G-CON Manufacturing Honored with the Korea Bioprocessing Excellence Award - PR Web - October 30th, 2020
- The Stem Cell-Derived Cells market to be in conjunction to growth from 2020 to 2030 - PRnews Leader - October 29th, 2020
- Harnessing regeneration of retinal tissues: An option almost within reach - Ophthalmology Times - October 23rd, 2020
- Regeneron, Trump, and the alleged hypocrisy of the pro-life movement - Christian Post - October 16th, 2020
- Stem Cell-Derived Cells Market Forecasted To Surpass The Value Of US$ XX Mn/Bn By 2019 - 2029 - Stock Market Funda - October 2nd, 2020
- Ghosh Addresses Brentuximab Vedotin Use in Advanced Hodgkin Lymphoma - Targeted Oncology - September 29th, 2020
- Researchers ID Role of Protein in Development of New Hearing Hair Cells - labmanager.com - September 22nd, 2020
- Convergence: EMA close to finalizing guidance for advanced therapies - Regulatory Focus - September 18th, 2020
- Stem Cells Market Report, History and Forecast 2020-2027, Data Breakdown by Manufacturers, Key Regions, Types and Application - News Degree - September 12th, 2020
- Innovative treatments for heart failure - Open Access Government - September 9th, 2020
- Japan Approves iPS Cell Therapy Trial for Spinal Cord ... - September 7th, 2020
- Optimized Freezing Solutions for Clinical Application of Cell Therapy Products - Technology Networks - September 3rd, 2020
- Stem Cell-Derived Cells Market Forecast to 2025: Global Industry Analysis by Top Players, Types, Key Regions and Applications - The Scarlet - August 30th, 2020
- Cell Therapy Processing Market is Booming Worldwide to Show Significant Growth by 2026 Cell Therapies Pty Ltd,Invitrx Inc.,Lonza Ltd,Merck & Co.,... - August 22nd, 2020
- On the move at the OneAZ, Spencer Fane, UArizona - AZ Big Media - August 20th, 2020
- Increasing Number of iPS Cell Therapies Tested in Clinical ... - August 17th, 2020
- Stem Cell-Derived Cells Market Forecasted To Surpass The Value Of US$ XX Mn/Bn By 2019 2029 - Owned - August 16th, 2020
- Opportunities in the Global Induced Pluripotent Stem Cell (iPS Cell) Industry - PRNewswire - August 11th, 2020
- Stem Cell-Derived Cells Market is Projected to Reach US$XX by the end of 2019 2029 - 3rd Watch News - July 10th, 2020
- Research and therapy with induced pluripotent stem cells ... - July 8th, 2020
- Hitachi and ThinkCyte to Develop an AI-driven Cell Analysis | ARC Advisory - ARC Viewpoints - July 6th, 2020
- Hitachi and ThinkCyte announce collaboration to develop an AI-driven cell analysis and sorting system - BioSpace - July 1st, 2020
- Global Stem Cells Market 2019 | How The Industry Will Witness Substantial Growth In The Upcoming Years | Exclusive Report By MRE - Cole of Duty - June 26th, 2020
- Induced Pluripotent Stem Cells (iPS) - UCLA Broad Stem ... - June 23rd, 2020
- Global Stem Cell Therapy Market 2020: Size, Share, Growth Rate, Revenue and Volume, Key-Players, Top Regions and Forecast Till 2025 - Cole of Duty - June 23rd, 2020
- Global Regenerative Medicine Market (2020 to 2024) - Size & Forecast with Impact Analysis of COVID-19 - ResearchAndMarkets.com - Business Wire - June 18th, 2020
- Vowing to never go back, Ex-con seeks to improve intolerable conditions in Israeli jails - Haaretz - June 8th, 2020
- Excellent growth of Human Embryonic Stem Cells Market- Comprehensive study by key players: Astellas Pharma Inc/ Ocata Therapeutics, Stemcell... - June 4th, 2020
- Global Stem Cell Partnering Deals Collection (2010-2020): Access to Headline, Upfront, Milestone and Royalty Data - PRNewswire - May 18th, 2020
- AgeX Therapeutics Reports First Quarter 2020 Financial Results and Provides Business Update - Insurance News Net - May 18th, 2020
- Global Stem Cell Partnering Terms and Agreements 2010-2020 - ResearchAndMarkets.com - Business Wire - May 18th, 2020
- AgeX Therapeutics Reports First Quarter 2020 Financial Results and Provides Business Update - Business Wire - May 15th, 2020
- Cell and Gene Therapy Catapult links with Japan's CiRA Foundation - PharmaTimes - May 13th, 2020
- Induced Pluripotent Stem Cell (iPSC) Media and Reagents ... - April 27th, 2020
- Evotec Regains Global Rights to Beta Cell Replacement Therapy - Yahoo Finance - April 22nd, 2020
- FDA Approves Tukysa to Treat Advanced or Metastatic HER2-Positive Breast Cancer - Curetoday.com - April 18th, 2020
- Researchers restore sight in mice by turning skin cells into light-sensing eye cells - National Institutes of Health - April 15th, 2020
- Chimeric Antigen Receptor (CAR) T-Cell Therapy Market 2020: Professional Survey & Competitive Dynamics Mustang Bio Inc., iCell Gene Therapeutics,... - April 12th, 2020
- Evotec Expands its iPSC-Based Cell Therapy Platform EVOcells Through Licensing Agreement with panCELLa | More News | News Channels -... - April 6th, 2020
- Evotec partners with panCELLa to enhance cell therapy plaform - ITResearchBrief.com - April 6th, 2020
- Evotec Expands its iPSC-Based Cell Therapy Platform EVOcells Through Licensing Agreement with panCELLa - BioSpace - April 2nd, 2020
- Optimizing the Production of AAV in Sf9 Insect Cells - Technology Networks - April 2nd, 2020
- The Progress & Ongoing Challenge of 3D Bioprinting Cardiac Tissue - 3DPrint.com - March 24th, 2020
- Stem Cell-Derived Cells Value Projected to Expand by 2019-2025 - 3rd Watch News - March 20th, 2020
- Looking to the future with Dr. Francis Collins - Newswise - March 17th, 2020
- Global induced pluripotent stem cells market is expected to grow with a CAGR of 8.6% over the forecast period from 2019-2025 - GlobeNewswire - March 13th, 2020
- Why are Pluripotent Stem Cells Important? Boston ... - March 12th, 2020
- Eye health: Testing the safety of stem cell therapy for age-related macular degeneration - Open Access Government - March 10th, 2020
- AgeX Therapeutics Researchers Publish Paper on the Age Reprogramming of Super-Centenarian Cells - Yahoo Finance - February 29th, 2020
- CAR T-Cell Therapy: Genetically Programming the Immune System to Attack Malignant Cells - Pharmacy Times - February 25th, 2020
- Stem Cell Therapy Contract Manufacturing Industry, 2019-2030 - Availability of Cutting-Edge Tools & Technologies has Emerged as a Differentiating... - February 17th, 2020
- Surge in the Adoption of Stem Cell-Derived Cells to Fuel the Growth of the Stem Cell-Derived Cells Market Through the Assessment Period 2019 2029 -... - February 17th, 2020
- NIH launches first U.S. clinical trial of patient-derived ... - February 4th, 2020
- Update on stem cell treatment cost for 2018 from ongoing ... - February 4th, 2020
- Team based at Osaka University carries out world's first transplant of heart cells generated from iPS cells - Medical Herald - January 31st, 2020
- Osaka University-based team successfully conducts first transplantation of cardiac muscle cells around the globe - Medical Herald - January 30th, 2020
- Osaka University transplants iPS cell-based heart cells in world's first clinical trial - The Japan Times - January 27th, 2020
- Kyoto University team gets OK from ministry for plan to transplant iPS-derived cartilage into knee joints - The Japan Times - January 25th, 2020
- The Kyoto University team's plan to transplant iPS cartilage into knee joints is OK - gotech daily - January 25th, 2020
- Psychiatric body condemns use of stem cell therapies to treat psychiatric disorders - Moneycontrol.com - January 20th, 2020
- Allele and Astellas Enter into an Expanded License for the Development of iPSC Lines - Business Wire - January 19th, 2020
- Cell Therapy And Tissue Engineering Market Size 2020 by Top Leading Companies- BioCardia Betalin Therapeutics, MEDIPOST Co., MaxCyte BioReliance... - January 16th, 2020
- Allele and Astellas Enter into an Expanded License for the Development of iPSC Lines - BioSpace - January 16th, 2020
- Where Are They Now? Top 3 Biotech Startups From NextGen Bio Class of 2018 - BioSpace - January 7th, 2020
- Global Stem Cell Therapy Market to Surpass US$ 40.3 Billion by 2027 Coherent Market Insights - Business Wire - December 18th, 2019
- Stem Cell-Derived Cells Market To Boost Demand And Forecast In Upcoming Year 2019 2029 - Downey Magazine - December 16th, 2019
- AgeX Therapeutics and Lineage Cell Therapeutics Announce Issuance of US Patent for Method of Generating Induced Pluripotent Stem Cells - Press Release... - December 15th, 2019
- Stem Cell-Derived Cells Market Expected to Expand at a Steady CAGR through 2019 2029 - Downey Magazine - December 15th, 2019
